Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Health Economics

Background:

• Cardiovascular disease (CVD) is a significant risk for patients with non-dialysis chronic kidney disease (CKD).
• Statins are known to reduce CVD risk, but optimal cost-effective regimens for CKD patients remain unclear.
• Evaluating combination therapy with statins and ezetimibe is crucial for managing CVD risk in this population.

Purpose of the Study:

• To assess the cost-effectiveness of different statin and ezetimibe regimens for CVD risk reduction in non-dialysis CKD patients.
• To compare the impact on quality-adjusted life years (QALYs) and healthcare costs in the United States (US) and United Kingdom (UK).
• To identify the most economically viable treatment strategy for preventing CVD in this high-risk group.

Main Methods:

• Utilized the Study of Heart and Renal Protection (SHARP) CKD-CVD policy model for analysis.
• Investigated statin monotherapy versus combination therapy with ezetimibe 10 mg.
• Estimated treatment effects based on low-density lipoprotein (LDL) cholesterol reduction and meta-analysis data.

Main Results:

• In the US, atorvastatin 40 mg increased QALYs by 0.23–0.31 at a net cost of $20,300–$78,200/QALY.
• Adding ezetimibe 10 mg provided additional QALYs (0.05–0.07) at a net cost of $43,600–$91,500/QALY, remaining cost-effective.
• Similar cost-effectiveness findings were observed in the UK, with thresholds below $100,000/QALY (US) and £20,000/QALY (UK).

Conclusions:

• Statin monotherapy is cost-effective for reducing CVD risk in non-dialysis CKD patients.
• Combination therapy with statins and ezetimibe 10 mg offers additional QALY gains and is also cost-effective.
• Evidence supports statin/ezetimibe combination therapy as a preferred strategy for CVD risk reduction in this patient group.